(Q35991204)

11 August 2017

Tuberculosis drug development: ensuring people living with HIV are not left behind (English)

1 reference

11 August 2017

1 reference

1

Anne F Luetkemeyer

1 reference

11 August 2017

5

Diane V Havlir

1 reference

11 August 2017

4

Christian Lienhardt

1 reference

11 August 2017

Haileyesus Getahun

2

1 reference

11 August 2017

Gabriel Chamie

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

25 August 2011

1 reference

American Journal of Respiratory and Critical Care Medicine

11 August 2017

1 reference

11 August 2017

184

1 reference

11 August 2017

10

1 reference

11 August 2017

1107-1113

1 reference

Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

TB and HIV integration: obstacles and possible solutions to implementation in South Africa

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Drugs in development for tuberculosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Rapid molecular detection of tuberculosis and rifampin resistance

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Global tuberculosis drug development pipeline: the need and the reality.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Timing of initiation of antiretroviral drugs during tuberculosis therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Running a tightrope: regulatory challenges in the development of antiretrovirals

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Building clinical trials capacity for tuberculosis drugs in high-burden countries

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

New approaches and emerging technologies in the diagnosis of childhood tuberculosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Viral hepatitis in HIV infection

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Multidrug-resistant tuberculosis management in resource-limited settings

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3361323

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

27 July 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Clinical impact of patient population differences and genomic variation in efavirenz therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Biomarkers for tuberculosis disease activity, cure, and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Biomarkers for tuberculosis disease activity, cure, and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201106-0995PP

HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality

21 January 2018

1 reference

12 December 2020

Treatment 2.0: catalysing the next phase of scale-up

1 reference

12 December 2020

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

12 December 2020

Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis

1 reference

12 December 2020

10.1164/RCCM.201106-0995PP

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

21868507

1 reference